{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:06:47Z","timestamp":1790719607361,"version":"4.1.0"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,12,9]],"date-time":"2017-12-09T00:00:00Z","timestamp":1512777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009940","name":"Lotto New Zealand","doi-asserted-by":"publisher","award":["353144"],"award-info":[{"award-number":["353144"]}],"id":[{"id":"10.13039\/501100009940","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EBioMedicine"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.ebiom.2017.11.030","type":"journal-article","created":{"date-parts":[[2017,12,13]],"date-time":"2017-12-13T03:49:33Z","timestamp":1513136973000},"page":"134-137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Steady-State Clozapine and Norclozapine Pharmacokinetics in Maori and European Patients"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3760-7896","authenticated-orcid":false,"given":"David B.","family":"Menkes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Glue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheung-Tak","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelyn","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2017.11.030_bb0005","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881110391123","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology","volume":"25","author":"Barnes","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ebiom.2017.11.030_bb0010","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/1039856215626644","article-title":"Antipsychotic prescribing and its correlates in New Zealand","volume":"24","author":"Dey","year":"2016","journal-title":"Australas. Psychiatry"},{"key":"10.1016\/j.ebiom.2017.11.030_bb0015","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3109\/10398562.2011.602078","article-title":"Clozapine use and outcomes among patients with treatment resistant schizophrenia","volume":"19","author":"El-Badri","year":"2011","journal-title":"Australas. Psychiatry"},{"key":"10.1016\/j.ebiom.2017.11.030_bb0020","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1742-7843.2005.pto_973160.x","article-title":"Assessment of CYP1A2 activity in clinical practice: why, how, and when?","volume":"97","author":"Faber","year":"2005","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.ebiom.2017.11.030_bb0025","author":"Food and Drug Administration"},{"key":"10.1016\/j.ebiom.2017.11.030_bb0030","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s40261-012-0004-6","article-title":"Evaluation of bioequivalence between clozapine suspension and tablet formulations \u2013 a multiple dose, fed and fasted study","volume":"32","author":"Glue","year":"2012","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.ebiom.2017.11.030_bb0035","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1055\/s-0031-1296207","article-title":"Plasma levels of clozapine and norclozapine in Mexican schizophrenia patients","volume":"61","author":"Gonz\u00e1lez-Esquivel","year":"2011","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.ebiom.2017.11.030_bb0040","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/JCP.0b013e3181acc372","article-title":"ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine","volume":"29","author":"Jaquenoud Sirot","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ebiom.2017.11.030_bb0045","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/00048670802415376","article-title":"Estimating the prevalence of schizophrenia among New Zealand Maori: a capture-recapture approach","volume":"42","author":"Kake","year":"2008","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.ebiom.2017.11.030_bb0050","first-page":"33","article-title":"Allele frequency differences of cytochrome P450 polymorphisms in a sample of New Zealand M\u0101ori","volume":"121","author":"Lea","year":"2008","journal-title":"N. Z. Med. J."},{"key":"10.1016\/j.ebiom.2017.11.030_bb0055","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1517\/17425255.2012.657626","article-title":"Cytochrome P450 variations in different ethnic populations","volume":"8","author":"McGraw","year":"2012","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ebiom.2017.11.030_bb0060","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00004850-200505000-00007","article-title":"An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels","volume":"20","author":"Ng","year":"2005","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.ebiom.2017.11.030_bb0065","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/00048670802345482","article-title":"Ethnic comparisons of antipsychotic use in schizophrenia","volume":"42","author":"Wheeler","year":"2008","journal-title":"Aust. N. Z. J. Psychiatry"}],"container-title":["EBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396417304747?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396417304747?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:49:46Z","timestamp":1762454986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396417304747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":13,"alternative-id":["S2352396417304747"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2017.11.030","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Steady-State Clozapine and Norclozapine Pharmacokinetics in Maori and European Patients","name":"articletitle","label":"Article Title"},{"value":"EBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2017.11.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}